Patient inclusion criteria:~* Diagnosis AD in early phase according to the IWG-2 criteria.~* Mini-Mental State
Examination (MMSE) Score ≥20.~* In-vivo evidence of AlzheimerÂ´s pathology (one of the following):~ * Decreased
AÎ²42 together with increased t-tau or p-tau in CSF.~ * Increased tracer retention on amyloid PET.~*
Availability of a next of kin who knows the patient well and is willing to accompany the subject to all trial
visits and give information about the patients functional level.~* Signed informed consent.~* The patient is
judged fitted for the study and capable to cooperate in treatment and follow-up.~* Ability to communicate in
Norwegian or another Scandinavian language.~
